Literature DB >> 22870425

Treatment of glucocorticoid-induced osteoporsis.

Gherardo Mazziotti1, Andrea Giustina, Ernesto Canalis, John P Bilezikian.   

Abstract

Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures occur in 30-50% of patients with GIO. Therefore, treatment of this disease is critical. Although patients should receive supplemental calcium and vitamin D, additional measures are necessary to prevent fractures. Estrogens and androgens may be of value in patients with hypogonadism, but bisphosphonates and teriparatide are the most effective agents in the treatment of GIO. Bisphosphonates prevent the early bone loss that follows exposure to glucocorticoids, and which has been attributed to increased resorption. Teriparatide appears to be more effective than alendronate in established GIO when reduced bone formation is the predominant pathophysiological mechanism. In conclusion, GIO can be prevented and treated with appropriate medical intervention.

Entities:  

Keywords:  bisphosphonates; glucocorticosteroids; osteoporosis; teriparatide

Year:  2009        PMID: 22870425      PMCID: PMC3382670          DOI: 10.1177/1759720X09343222

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  58 in total

Review 1.  Growth hormone in glucocorticoid-induced osteoporosis.

Authors:  F Manelli; R Carpinteri; S Bossoni; A Burattin; S Bonadonna; E Agabiti Rosei; A Giustina
Journal:  Front Horm Res       Date:  2002       Impact factor: 2.606

Review 2.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

3.  The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Authors:  Shreyasee Amin; Michael P Lavalley; Robert W Simms; David T Felson
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

4.  Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

Authors:  Philip N Sambrook; Mark Kotowicz; Peter Nash; Colin B Styles; Vasi Naganathan; Kathy N Henderson-Briffa; John A Eisman; Geoff C Nicholson
Journal:  J Bone Miner Res       Date:  2003-05       Impact factor: 6.741

5.  Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment.

Authors:  Bronwyn A L Crawford; Peter Y Liu; Mary T Kean; Jane F Bleasel; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

6.  Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.

Authors:  Q Rehman; T F Lang; C D Arnaud; G W Modin; N E Lane
Journal:  Osteoporos Int       Date:  2003-01       Impact factor: 4.507

7.  Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.

Authors:  Elizabeth Shane; Vicki Addesso; Pearila B Namerow; Donald J McMahon; Shaw-Hwa Lo; Ronald B Staron; Mark Zucker; Susan Pardi; Simon Maybaum; Donna Mancini
Journal:  N Engl J Med       Date:  2004-02-19       Impact factor: 91.245

8.  Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy.

Authors:  Dominique Simon; Nadine Lucidarme; Anne-Marie Prieur; Jean Charles Ruiz; Paul Czernichow
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

9.  Bone mass development and bone metabolism in juvenile idiopathic arthritis: treatment with growth hormone for 4 years.

Authors:  Susanne Bechtold; Peter Ripperger; Walter Bonfig; Heinrich Schmidt; Harro Bitterling; Renate Häfner; Hans Peter Schwarz
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

10.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David M Reid; Jean-Pierre Devogelaer; Kenneth Saag; Christian Roux; Chak-Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

View more
  3 in total

Review 1.  Premenopausal bone health: osteoporosis in premenopausal women.

Authors:  Alice Abraham; Adi Cohen; Elizabeth Shane
Journal:  Clin Obstet Gynecol       Date:  2013-12       Impact factor: 2.190

2.  Inhibition of Cdk5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice.

Authors:  Benjamin Thilo Krüger; Lena Steppe; Sabine Vettorazzi; Melanie Haffner-Luntzer; Sooyeon Lee; Ann-Kristin Dorn; Anita Ignatius; Jan Tuckermann; Mubashir Ahmad
Journal:  Biomedicines       Date:  2022-02-08

Review 3.  A Jack of All Trades: Impact of Glucocorticoids on Cellular Cross-Talk in Osteoimmunology.

Authors:  Mubashir Ahmad; Yasmine Hachemi; Kevin Paxian; Florian Mengele; Mascha Koenen; Jan Tuckermann
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.